EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs
Proven results for the treatment of canine otitis externa. Harnessing the potency of hydrocortisone aceponate (HCA), the broad-spectrum efficacy of gentamicin, and the consistent results of miconazole.
Pet owners reported rapid relief, sustained resolution of signs and high levels
of satisfaction in a recent evaluation of EASOTIC Otic Suspension. Read more. Click Here
Access the EASOTIC Page for Pet Owners
- Proven results for the treatment of canine otitis externa (OE) - With 3 hard-working ingredients:
- Hydrocortisone aceponate (HCA) - Potent New Generation Glucocorticoid
- Novel anti-inflammatory glucocorticoid with high benefit/risk ratio10
- High Potency: A highly lipophilic diester topical steroid
- Rapidly Absorbed: 60 times more lipophilic (fat soluble) than hydrocortisone resulting in quick and effective dose concentrations reached in epidermis and dermis5,10
- Pro-Drug: Providing anti-inflammatory action to the targeted tissues5,6
- Proven efficacy lasting beyond the 5 day treatment protocol1
- Acts locally with minimal systemic side effects; Once HCA reaches systemic circulation, most has been converted to a much weaker metabolite, hydrocortisone5,7
- Gentamicin sulfate – Proven antimicrobial
- Broad-spectrum antimicrobial for first line use 4,6
- Excellent safety profile8
- Miconazole nitrate - Broad-spectrum antifungal
- Proven consistent results 1, 4, 9
- Hydrocortisone aceponate (HCA) - Potent New Generation Glucocorticoid
- Ideal for for patients with acute OE or acute recurrent OE
- 1 mL (a single pump) in each ear, once per day for 5 days—for any size dog
- Improved owner compliance3
- Unique, airless delivery system allows for easy administration regardless of dog’s position
- Flexible nozzle does not irritate inflamed and sensitive ears
- Each bottle contains 10 mL or 10 doses
- Enough for 5 days of bilateral treatment
![23_icon_dark.png]()
Shop Virbac on Vetcove
You can shop all Virbac products on Vetcove and connect your distributor accounts to purchase and access rewards.
Pet Owner Information:
We have a separate site specifically tailored to pet owners with all the information you need to ensure your pets are taken care of to the highest degree! Click here to view this product's page on our pet owner website!
Important Safety Information
EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs: For otic (ear) use in dogs only. Contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics. Do not use in dogs with known tympanic membrane (ear drum) perforation. The safe use of EASOTIC Otic Suspension in dogs used for breeding purposes has not been evaluated. Do not administer orally. Humans with known or suspected hypersensitivity to hydrocortisone, aminoglycoside antibiotics, or azole antifungals should not handle this product. For complete information or to obtain a package insert, contact Virbac at 1‐800‐338‐3659, or download here.
References:
1. Rigaut D, Sanquer A, Maynard L, Reme CA. Efficacy of a topical ear formulation with a pump delivery system for the treatment of infectious otitis externa in dogs: a randomized controlled trial. Intern J Appl Res Vet Med. 2011;9(1):15–28.
2. Rey-Grobellet X, Rigaut D, Maynard L, Rème CA. Persistence of antimicrobials in the ear canal of dogs treated once daily for 5 days with 1 ml of a topical ear formulation. Virbac SA, Carros, F-06511 France; 2010.
3. Boda C, Liege P, Reme C. Evaluation of owner compliance with topical treatment of acute otitis externa in dogs: a comparative study of two auricular formulations. Intern J Appl Res Vet Med. 2011;9(2):157–165.
4. Lyskova P, Vydrzalova M, Mazurova J. Identification and antimicrobial susceptibility of bacteria and yeasts isolated from healthy dogs and dogs with otitis externa. J Vet Med. 2007;A54:559–563.
5. Schackert C, Korting HC, Schäfer-Körting M. Qualitative and quantitative assessment of the benefit/risk ratio of medium potency topical corticosteroids in vitro and in vivo. BioDrugs. 2000;13(4):267–277.
6. Hariharan,Harry, McPhee, Lynn, Heaney,Susan, Bryenton, James; Antimicrobial drug susceptibility of clinical isolates of Pseudomanas aeruginosa. Can Vet J 1995; 36:166-168
7. Guaguere E, Bensignor E, Carlotti DN, et al. Clinical practice guidelines on the best use of topical glucocorticoids in canine dermatology. Prat Med Chir Anim Comp. 2011;46:S1–S20.
8. Strain GM, Merchant SR, Neer TM, Tedford BL. Ototoxity assessment of a gentamicin sulfate otic preparation in dogs. Am J Vet Res. 1995;56:532–538.
9. Barasch,Andrei, Griffin, Andreea Voinea. Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials
10. Schäfer-Körting M, Gysler A. Topical glucocorticoids with improved benefit/risk ratio. In: Korting HC, Schäfer-Körting M, eds. The Benefit/Risk Ratio: A Handbook for The Rational Use of Potentially Hazardous Drugs. Boca Raton, FL: CRC Press; 1999:359–372.
Ingredients:
ACTIVE INGREDIENTS: Contains 1.11 mg/mL hydrocortisone aceponate, 17.4 mg/mL miconazole nitrate, and 1.5 mg/mL gentamicin (as sulfate).